Whitehawk Operating Cycle from 2010 to 2026

WHWK Stock   2.85  0.07  2.52%   
Whitehawk Therapeutics Operating Cycle yearly trend continues to be quite stable with very little volatility. Operating Cycle may rise above 176.89 this year. From the period between 2010 and 2026, Whitehawk Therapeutics, Operating Cycle regression line of its data series had standard deviation of  60.76 and standard deviation of  60.76. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
136.6
Current Value
176.89
Quarterly Volatility
60.76353026
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Whitehawk Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Whitehawk Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 117.5 K, Interest Expense of 131.7 K or Selling General Administrative of 26.4 M, as well as many indicators such as Price To Sales Ratio of 3.59, Dividend Yield of 0.0165 or PTB Ratio of 1.54. Whitehawk financial statements analysis is a perfect complement when working with Whitehawk Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Whitehawk Stock
Check out the analysis of Whitehawk Therapeutics Correlation against competitors.
For more information on how to buy Whitehawk Stock please use our How to buy in Whitehawk Stock guide.

Latest Whitehawk Therapeutics' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Whitehawk Therapeutics over the last few years. It is Whitehawk Therapeutics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Whitehawk Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Very volatile
   Operating Cycle   
       Timeline  

Whitehawk Operating Cycle Regression Statistics

Arithmetic Mean143.04
Geometric Mean133.97
Coefficient Of Variation42.48
Mean Deviation28.83
Median138.83
Standard Deviation60.76
Sample Variance3,692
Range290
R-Value0
Mean Square Error3,938
R-Squared0.000023
Significance0.99
Slope0.06
Total Sum of Squares59,075

Whitehawk Operating Cycle History

2026 176.89
2025 136.6
2024 118.79
2023 127.59
2021 64.65
2020 354.21

About Whitehawk Therapeutics Financial Statements

Whitehawk Therapeutics investors utilize fundamental indicators, such as Operating Cycle, to predict how Whitehawk Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle 136.60  176.89 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Whitehawk Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Whitehawk Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Whitehawk Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Whitehawk Therapeutics Stock:
Check out the analysis of Whitehawk Therapeutics Correlation against competitors.
For more information on how to buy Whitehawk Stock please use our How to buy in Whitehawk Stock guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Whitehawk Therapeutics. If investors know Whitehawk will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Whitehawk Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.64)
Revenue Per Share
0.28
Quarterly Revenue Growth
0.335
Return On Assets
(0.54)
Return On Equity
(0.14)
The market value of Whitehawk Therapeutics is measured differently than its book value, which is the value of Whitehawk that is recorded on the company's balance sheet. Investors also form their own opinion of Whitehawk Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Whitehawk Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Whitehawk Therapeutics' market value can be influenced by many factors that don't directly affect Whitehawk Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Whitehawk Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Whitehawk Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Whitehawk Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.